Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ®

Core Points - Valneva SE has received marketing authorization from the UK for IXCHIQ®, the world's first chikungunya vaccine, which is a single-dose vaccine for individuals aged 18 and older [1][3] - The approval is based on Phase 3 data showing that IXCHIQ® induces a strong immune response that can last for at least three years [2] - Valneva has received regulatory approvals for IXCHIQ® in the US, Europe, and Canada, and expects approval in Brazil in Q1 2025 [3] Company Developments - The Chief Medical Officer of Valneva emphasized the importance of the vaccine for UK travelers, especially given the current chikungunya outbreak in India, which has seen 370,000 cases reported from January 2019 to July 2024 [4] - Valneva has partnered with CEPI to support late-stage development and expand access to IXCHIQ® in low- and middle-income countries, with a $41.3 million grant from the EU to facilitate this [5][11] - An exclusive license agreement with the Serum Institute of India has been signed to supply the vaccine in Asia at affordable prices [6] Industry Context - Chikungunya is a mosquito-borne viral disease that has been spreading globally since 2004, with over 3.7 million cases reported in the Americas between 2013 and 2023 [9] - The World Health Organization has identified chikungunya as a major public health problem, with the disease's economic impact expected to grow due to climate change [9][10]